Lilly’s Jaypirca Blazes Leukemia Trail with FDA Nod, Fast Confirmatory Trial Filing

On Dec.1, the FDA granted accelerated approval to Lilly’s Jaypirca for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.